Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR
topical product
OTTAWA, ONTARIO--(Marketwired - Feb. 1, 2017) - PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra
Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP), a pharmaceutical company focused on
developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions
announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its
planned clinical trial for PhytoPain Topical Gel Relief ("PPTGR"), being developed as a locally administered therapeutic for the
treatment of Chemotherapy-Induced Neuropathic Pain ("CIPN").
CIPN is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment
early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily
stopping it. In other patients the symptoms of CIPN may last for months or years after the cancer therapy has
stopped. CIPN symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of
these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the
symptoms of CIPN and avoid exposing some patients to oral neuropathic pain analgesics.
The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its
adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical
fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the
future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue",
"expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations
on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties,
many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ
materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to
differ materially from current expectations include, among other things, without limitation, the inability of the Company,
through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to
obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated
costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or
events to differ materially from those described in forward-looking statements, there may be other factors that cause results or
events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news release are made as of the date of this news release and
the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable securities legislation.